Is INCY or INO more undervalued in 2026?

CirclFi compares Incyte Corporation (INCY) and Inovio Pharmaceuticals, Inc. (INO) using 13 institutional-grade valuation models. INCY has a Quality of Company score of 6.4/10 while INO scores 4.3/10.

Which is a better buy — INCY or INO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do INCY and INO valuations compare?

INCY at $97.50 and INO at $1.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

INCY vs INO Valuation Comparison 2026 — Intrinsic Value Analysis

INCY

Biotechnology

Incyte Corporation

Quality

6.4

out of 10

Value Trap

SAFE

Price

$97.50

Last close

Models

13/13

Active

INO

Biotechnology

Inovio Pharmaceuticals, Inc.

Quality

4.3

out of 10

Value Trap

WARN

Price

$1.30

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	INCY Fair Value	INCY Upside	INO Fair Value	INO Upside
Bayesian DCF	Intrinsic	$48.88	-49.9%	$0.48	-63.1%
Earnings Power Value	Intrinsic	$86.80	-11.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$26.71	-72.6%	$2.08	+60.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for INCY vs INO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INCY vs INO — Which Stock Is More Undervalued?

INCY scores higher with a 6.4/10 quality rating vs INO's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Incyte Corporation (INCY) and Inovio Pharmaceuticals, Inc. (INO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INCY currently trades at $97.50 with a QOC of 6.4/10, while INO trades at $1.30 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).